Leadership Team


 

Anup Dam

Anup Dam, Chairman & Manager

As founder of STI Pharma, LLC, Anup Dam has utilized more than 25 years of biomedical and related industry experience in creating STI’s current core business.


Mr. Dam began his pharmaceutical industry career in 1986 at G. D. Searle (now Pfizer) and was an integral part of an industry/NIH joint project between Abbott Laboratories, Searle and NIH. Mr. Dam then rose to a senior leadership position at Carter-Wallace.


Mr. Dam has held several senior leadership positions including Lead Analyst in the successful approval of the first new drug in the 1990’s for epilepsy and the first non-steroid nasal spray for allergies. In addition, he has actively contributed to NDAs in the therapeutic areas of CNS, Cardiology, Infectious Disease and Allergy/Immunology. He has collaborated in the publication of several articles describing the results of clinical trials in patients with allergies and asthma.


Mr. Dam’s vision is to establish STI Pharma as a generic and branded pharmaceutical company offering products which offer unique solutions for therapeutic needs. STI Pharma has established an experienced and effective sales and marketing team, reliable manufacturing partners and an efficient distribution system. STI Pharma continually searches for opportunities to provide high quality therapeutics for acquisition and marketing. Mr. Dam also wishes to develop new formulation technologies to facilitate the administration of therapeutics as well as repurpose therapeutics for new indications.


Mr. Dam obtained an M.S. in Statistics from the University of Illinois and also from Dhaka University.


 


Vincent Bilinsky

Vincent Bilinsky, Sr. VP, Sales & Marketing

Mr. Bilinsky has over 30 years of experience in the Pharmaceutical industry with Bristol-Myers Squibb(BMS) and Smith Kline & French Laboratories. He has held executive positions as Vice President, Apothecon Sales; and Vice President, Trade Sales/Operations for BMS. In these roles Mr. Bilinsky has directed Sales, Trade Sales and Operations for both branded and generic products. These activities include the management of customer service operations, the launch of all BMS new product Trade distribution activities, inventory management, direct responsibility for channel customer management, contract negotiations and management, channel customer and primary customer interface for all industry Trade Associations for BMS. During his career, Mr. Bilinsky has developed strong business relationships with senior executives from all National Trade Associations. He also has a detailed understanding of multiple market segment interdependencies related to manufacturers, wholesalers, chain, independent, mail and hospital pharmacies and payers. Mr. Bilinsky has designed and executed distribution models and strategies to maximize breadth and speed of distribution of new primary care and specialty pharmaceuticals for BMS as a major part of his responsibility.


Mr. Bilinsky received a B.A. in Political Science from Arkansas State University.



Frank J. Valenti

Frank J. Valenti, Vice President, Sales & Marketing

Mr. Valenti is a senior executive who has displayed over his 36 year career a successful track record in the pharmaceutical and consumer products industry. An alumnus of Bristol Myers Squibb, Mr. Valenti over a 32 year career developed extensive experience and expertise across a broad base of business operational and therapeutic areas: Diabetes, HIV, CNS, Dermatological, Cardiovascular, OTC Drugs, Antibiotics, Oncology and Arthritis. He has held executive positions as Vice President of Sales of BMS Dermatological division, WestwoodSquibb; Area Vice President of Bristol Myers Squibb's Cardiovascular/Diabetes division; and National Director of Chain Sales for Bristol Myers Squibb Trade Sales organization. As a industry consultant, Mr. Valenti developed particular expertise and interest in Pharmacy Trade Relations. Throughout the course of his career, he has established a widespread network of senior executive business relationships across the various customer segments which include: Retail Pharmacy, Chain Drugs, Mass Merchandisers, Food Chains, Club Stores, Drug Wholesalers, Specialty Pharmacy, and National Trade Associations.


Mr. Valenti received a B.S. in Business Management from the University of New Haven.



Dave Counts

David F. Counts, Ph.D. , VP, Operations

Dr. Counts has over 30 years experience in the Pharma/Biotech Industry. His experiences include research, product development, business development, acquisition of companies while at Marion Labs (American Biomaterials, now Integra Life Sciences), as well as negotiation of co-development agreements with both biotech companies and universities. He is the author of over 50 abstracts, publications and patents. Dr. Counts was Associate Vice President for technology evaluation and licensing at BTG in the US with a focus on the areas of inflammation and infectious diseases. As such, he acquired and licensed technologies from companies (DuPont-Merck and Biogen) and universities. Dr. Counts has helped start two biotech companies and one cosmetic company. In those companies, he was responsible for product development and negotiated contracts for external work, as well as management of in-house development activities. He currently advises Thomas Jefferson Medical College Technology Transfer Office, the Nanotechnology Institute and Portland State University Department of Innovation & Intellectual Property on technology valuation, company formation and licensing of technology.


Dr. Counts received his BS from Tulane University and his MS and Ph.D. from the Medical College of Georgia.


 


Michael Stalhamer

Michael E. Stalhamer, VP Regulatory Affairs & Product Development

Mr. Stalhamer joined STI Pharma in 2009. He has over 15 years experience in biotechnology and medical device research, engineering, facility and equipment design, regulatory affairs, quality assurance and marketing with companies such as Merck, Novartis, Heritage, Amylin Pharmaceuticals and GlaxoSmithKline Pharmaceuticals. During that time, he managed facility upgrades, progressing products from Phase II/III through to commercialization of sterile and non sterile pharmaceutical products as well as medical devices. He has worked closely with the FDA in putting together IND/NDA/ANDA and PMA submissions and gaining timely approval of a number of both pharmaceutical and medical device products in a variety of therapeutic areas.   He also has experience in negotiating and managing development contracts for the launch and manufacturing of generic as well as branded products. 


He received his M.S. from New Jersey Institute of Technology and his BS from Rutgers University.